FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$2.33

Market cap

$279.18M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.05

Enterprise value

$312.38M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 37

Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform ...

Highlights
FATE's EPS is up by 28% year-on-year and by 3.7% since the previous quarter
The net income has grown by 27% YoY and by 3% from the previous quarter
The gross profit has declined by 23% year-on-year but it has increased by 2.8% since the previous quarter
FATE's revenue is down by 23% year-on-year but it is up by 2.8% since the previous quarter
The company's equity fell by 41% YoY and by 15% QoQ
The company's quick ratio fell by 38% YoY and by 17% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT PTCT BDX NBIX

Key stats

What are the main financial stats of FATE

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
-4.9%
1 week
-9.34%
1 month
-17.67%
1 year
109.91%
YTD
137.13%
QTD
-13.7%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$6.49M
Gross profit
$6.49M
Operating income
-$133.59M
Net income
-$126M
Gross margin
100%
Net margin
-1,941.1%
FATE's operating income is up by 31% year-on-year and by 4.2% since the previous quarter
The net income has grown by 27% YoY and by 3% from the previous quarter
The gross profit has declined by 23% year-on-year but it has increased by 2.8% since the previous quarter
FATE's revenue is down by 23% year-on-year but it is up by 2.8% since the previous quarter

Price vs fundamentals

How does FATE's price correlate with its fundamentals

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.77
P/S
43.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.12
FATE's EPS is up by 28% year-on-year and by 3.7% since the previous quarter
FATE's price to book (P/B) is 77% higher than its last 4 quarters average of 1.0 but 23% lower than its 5-year quarterly average of 2.3
The company's equity fell by 41% YoY and by 15% QoQ
The stock's price to sales (P/S) is 55% more than its last 4 quarters average of 27.9 and 27% more than its 5-year quarterly average of 33.9
FATE's revenue is down by 23% year-on-year but it is up by 2.8% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
The ROE has contracted by 17% YoY and by 11% from the previous quarter
FATE's return on sales is up by 6% since the previous quarter and by 4.1% year-on-year
The ROIC has contracted by 6% from the previous quarter and by 6% YoY
Fate Therapeutics's return on assets has decreased by 6% QoQ and by 3.7% YoY

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is 144% greater than its total liabilities
FATE's current ratio is down by 40% YoY and by 17% from the previous quarter
The company's quick ratio fell by 38% YoY and by 17% QoQ
The debt is 51% smaller than the equity
The company's debt to equity has surged by 58% YoY and by 14% QoQ
The company's equity fell by 41% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.